GLP-1's release is stimulated by certain foods and gut microbes, and its mechanism of action is mimicked by drugs like semaglutide (the ingredient behind Ozempic). People with type 2 diabetes ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on developing treatments for liver disease and obesity, has been garnering attention ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for inflammatory diseases. COYA 303 is an investigational biologic combination ...

Association does not imply causation, and the mechanism of action of these agents ... of patients who filled a prescription for a GLP-1 within at least 90 days before and after surgery and ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

Biomea Fusion (BMEA) announced the company will become a diabetes and obesity medicines company. Based on the most recent clinical trial ...